Cancer Health Forums

Lung Cancer Forums => Living with Lung Cancer => Topic started by: iana5252 on June 07, 2019, 09:28:57 am

Title: Keytruda shatters stats on lung cancer long-term survival
Post by: iana5252 on June 07, 2019, 09:28:57 am
This news came out of ASCO, a big cancer doctor gathering in Chicago held in June every year. Here's some of Cancer Health's coverage of the news.


The checkpoint inhibitor Keytruda (pembrolizumab) continues to be a safe and effective treatment for non-small-cell lung cancer (NSCLC), leading to an improvement in overall survival at five years, according to long-term follow-up data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

In the KEYNOTE-001 study, which began enrollment at the dawn of the immunotherapy era, nearly a quarter of people who had not previously been treated with chemotherapy and about 15% of treatment-experienced patients were still alive five years later, reported Edward Garon, MD, of the UCLA David Geffen School of Medicine in Los Angeles. In contrast, people treated with chemotherapy historically had a five-year survival rate of around 5% before the arrival of immunotherapy.

β€œThe uniformly negative outlook that has been associated with a diagnosis of advanced non-small-cell lung cancer is certainly no longer appropriate,” Garon said. β€œThe fact that we have patients on this trial that are still alive after seven years is quite remarkable. We also have evidence that most patients who are doing well after two years on pembrolizumab live for five years or more.”